What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Events
Type
Format
BANNER
BANNER
  • Standard of care
  • Efficacy
  • Safety

    TAFINLAR + MEKINIST is the first and only† targeted treatment for low-grade paediatric glioma with BRAF V600E mutations who require systemic therapy1,2

     

    †As of July 2025

    Surgery aimed at maximal safe surgical resection followed by first-line chemotherapy is the current first-line treatment for most paediatric patients with LGG. The use of radiotherapy is typically reserved for older patients (>3 years) or those refractory to medical therapy.3

    Paediatric patients treated with TAFINLAR + MEKINIST had fewer Grade ≥3 adverse events compared with chemotherapy (47% vs 94%)4

     

    Adverse events (safety population)

    Table
    AE

TAFINLAR + MEKINIST demonstrated significantly higher ORR compared with chemotherapy in paediatric patients with low-grade glioma†4

 

†Patients treated with TAFINLAR + MEKINIST had an ORR of 47% compared with 11% for those treated with chemotherapy (95% CI: 1.7–11.2; p<0.001)4

 

Primary endpoint: Objective response rate4

Objective response rate

TAFINLAR + MEKINIST significantly improved PFS compared with chemotherapy in paediatric patients with low-grade glioma†4

 

Progression-free survival4

 

 

 

Graph2
Overall survival

TAFINLAR and MEKINIST PBS Information: Authority Required. Please refer to PBS Schedule for full authority information for products.

▼ These medicinal products are subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

For Australian healthcare professionals only. Please review Product Information before prescribing. For TAFINLAR Product Information, please click here. For MEKINIST Product Information, please click here. Alternatively, contact med info on 1800 671 203 to access the full Product Information.

 

Footnotes and References

Abbreviations: CI, confidence interval; HR, hazard ratio; ORR, objective response rate; OS, overall survival; PBS, Pharmaceutical Benefits Scheme; PFS, progression-free survival.


References: 1. TAFINLAR (dabrafenib) Australian approved product information. 2. MEKINIST (trametinib) Australian approved product information. 3. Sait SF, et al. Curr Neurol Neurosci Rep. 2023;23(4):185–199. 4. Bouffet E, et al. N Engl J Med. 2023;389:1108–1120